



Genenta presents company's pipeline and the **preliminary clinical data** from Phase I/II in patients affected with glioblastoma multiforme at the *Advanced Therapies Congress & Expo 2020*

September 08, 2020

MILAN (Italy) / NEW YORK (NY, USA) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they will present data from the TEM-GBM study at the *Advanced Therapies Congress & Expo 2020*.

Dr. Carlo Russo, Chief Medical Officer and Head of Development at Genenta, will provide an overview of Temferon™, the company's pipeline and the latest preliminary clinical data in patients affected with glioblastoma multiforme, on September 9, at 6.50pm CET.

Registration at: <https://www.terrapinn.com/congress/advanced-therapies/index.stm>.

About Genenta Science

Genenta (www.genenta.com) has developed a strategy for ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to delivery immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Genenta's proprietary product is Temferon™.

The targeted expression of the immunomodulatory molecule in TEMs is achieved combining a transcriptional and post-transcriptional microRNA-mediated control. Thanks to these mechanisms, TEMs become capable of expressing the immunomodulatory molecule interferon-alpha (IFN- α) in the tumor microenvironment.

TEMs are endowed with a pro-angiogenic activity and are spontaneously and actively recruited by developing tumors to sustain their growth. Thanks to the immune-gene transfer, TEMs become the tool for the local delivery of the immunomodulatory molecule. In preclinical models, the local IFN- α release triggered both a direct (anti-angiogenic, pro-apoptotic) and an indirect anti-tumor effect (immune response).

In contrast to antigen-restricted Chimeric Antigen Receptor T cells (CAR-T), Temferon™ is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, which remains one of the main unresolved challenge in Immuno oncology. In addition, its immune-modulatory functions may trigger a long-lasting immune response towards multiple tumor antigens.

As a result, Temferon™ should be able to break the tumor-induced immune tolerance by reprogramming the tumor immune microenvironment.

Temferon is under investigation in a Phase I/II clinical trial in newly diagnosed Glioblastoma Multiforme patients.

Genenta's headquarter is in Milan (Italy) with an office in Alexandria Center's LaunchLabs, New York (NY, USA). The Company is part of Assobiotech, Italia StartUp, and ELITE (London Stock Exchange Group).

Co-founders: Pierluigi Paracchi, Ospedale San Raffaele (OSR), Prof. Luigi Naldini (Director SR-TIGET, San Raffaele Telethon Institute for Gene Therapy), and Dr. Bernhard Gentner (Hematologist and Physician-Scientist at OSR and SR-TIGET). Dr. Carlo Russo, MD serves as CMO & Head of Development. Genenta has raised more than €30M in three different rounds of financing.

Genenta Media/Investor Contact:

Valentina Brambilla, MSc
+39 388 789.15.41
valentina.brambilla@genenta.com

GENENTA SCIENCE Srl

Ospedale San Raffaele - DiBit 1 - Via Olgettina, 58 - 20132 Milan (Italy)
LaunchLabs - Alexandria Center, 14th Floor –
430 East 29th Street - New York, NY 10016 (USA)